Janssen Pharmaceuticals v. A.Y.

|

(U.S., filed March 8, 2021): Urging the Court to address whether FDA regulations permit a manufacturer unilaterally to implement an off-label warning via a CBE or does the addition of an off-label warning require FDA approval.

View Amicus Brief

Case not yet decided

Latest News

View all news